Status:
COMPLETED
The Clinical Evaluation of the Dose of Erythropoietins Trial
Lead Sponsor:
Giovanni FM Strippoli, MD
Conditions:
Kidney Failure, Chronic
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Anaemia is a risk factor for death, cardiac-cerebrovascular events and poor quality of life in patients with chronic kidney disease (CKD). Erythropoietin Stimulating Agents (ESAs) are the most used tr...
Detailed Description
Phase III pragmatic, randomized-controlled trial comparing different doses of ESAs in patients with renal anaemia. Study Sample: Total of 900 participants from Italy Background and Rationale: Anae...
Eligibility Criteria
Inclusion
- Age \> = 18,
- End stage kidney disease and anemia
- Treatment with hemodialysis for renal replacement therapy
- no contraindications to erythropoietin stimulating agents (ESAs) or already treated with ESAs
Exclusion
- Patients with Hb levels \> 10 g/dl without ESAs
Key Trial Info
Start Date :
July 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2014
Estimated Enrollment :
656 Patients enrolled
Trial Details
Trial ID
NCT00827021
Start Date
July 1 2009
End Date
July 1 2014
Last Update
July 19 2016
Active Locations (41)
Enter a location and click search to find clinical trials sorted by distance.
1
Ospedale Beato Angelo
Acri, Italy
2
Ospedale S. Giovanni Di Dio
Agrigento, Italy
3
Ospedale Civile di Alghero ASL n°1
Alghero, Italy
4
Ospedali Riuniti di Anzio e Nettuno
Anzio, Italy